Status: Not yet recruiting
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
Participants needed: 65
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Rapa Therapeutics LLCUpdated: Mar 19, 2026Locations: 1
Eligibility criteria
Male or female patients ≥ 18 years of age. [+15]
Other active malignancy (except non-melanoma skin cancer). [+11]